Andreas Argyrides
Stock Analyst at Wedbush
(4.34)
# 464
Out of 4,667 analysts
97
Total ratings
45.31%
Success rate
22.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Reiterates: Outperform | $181 | $124.38 | +45.52% | 9 | Nov 15, 2024 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $35 | $10.66 | +228.33% | 1 | Oct 16, 2024 | |
| LRMR Larimar Therapeutics | Initiates: Outperform | $26 | $6.08 | +327.63% | 1 | Oct 16, 2024 | |
| RGLS Regulus Therapeutics | Reiterates: Outperform | $7 | $1.40 | +400.00% | 1 | Aug 14, 2024 | |
| RANI Rani Therapeutics Holdings | Initiates: Outperform | $17 | $2.05 | +729.27% | 4 | Aug 2, 2024 | |
| LQDA Liquidia | Initiates: Perform | n/a | $10.12 | - | 6 | Jun 25, 2024 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | $104 | $49.82 | +108.75% | 14 | Jun 25, 2024 | |
| KROS Keros Therapeutics | Initiates: Outperform | $102 | $54.14 | +88.40% | 5 | Jun 25, 2024 | |
| CLSD Clearside Biomedical | Initiates: Outperform | $5 | $1.05 | +376.19% | 1 | Jun 25, 2024 | |
| GOSS Gossamer Bio | Initiates: Outperform | $9 | $0.70 | +1,192.18% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $13.55 | +40.22% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $9 | $4.74 | +90.07% | 4 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $14.91 | +94.50% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $9.63 | +118.07% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $110.86 | +102.06% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $17.03 | +234.70% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.17 | - | 6 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $1.07 | +554.21% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $6.88 | +45.35% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $1.95 | +412.82% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $62.56 | +11.89% | 6 | Aug 1, 2023 |
Ascendis Pharma
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $124.38
Upside: +45.52%
Benitec Biopharma
Oct 16, 2024
Initiates: Outperform
Price Target: $35
Current: $10.66
Upside: +228.33%
Larimar Therapeutics
Oct 16, 2024
Initiates: Outperform
Price Target: $26
Current: $6.08
Upside: +327.63%
Regulus Therapeutics
Aug 14, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.40
Upside: +400.00%
Rani Therapeutics Holdings
Aug 2, 2024
Initiates: Outperform
Price Target: $17
Current: $2.05
Upside: +729.27%
Liquidia
Jun 25, 2024
Initiates: Perform
Price Target: n/a
Current: $10.12
Upside: -
MoonLake Immunotherapeutics
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $49.82
Upside: +108.75%
Keros Therapeutics
Jun 25, 2024
Initiates: Outperform
Price Target: $102
Current: $54.14
Upside: +88.40%
Clearside Biomedical
Jun 25, 2024
Initiates: Outperform
Price Target: $5
Current: $1.05
Upside: +376.19%
Gossamer Bio
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $0.70
Upside: +1,192.18%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $13.55
Upside: +40.22%
Mar 7, 2024
Maintains: Outperform
Price Target: $4 → $9
Current: $4.74
Upside: +90.07%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $14.91
Upside: +94.50%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $9.63
Upside: +118.07%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $110.86
Upside: +102.06%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $17.03
Upside: +234.70%
Nov 16, 2023
Upgrades: Outperform
Price Target: n/a
Current: $1.17
Upside: -
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $1.07
Upside: +554.21%
Oct 10, 2023
Initiates: Outperform
Price Target: $10
Current: $6.88
Upside: +45.35%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $1.95
Upside: +412.82%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $62.56
Upside: +11.89%